Labviva's AI Procurement Shield: How a Private Startup is Saving Pharma R&D from Supply Chain Inflation

Labviva is winning in life sciences not by improving what happens at the bench, but by transforming what happens before anything reaches it.

By Carry and Conquer Publications

Every year, pharmaceutical companies and research institutions spend billions of dollars on reagents, chemicals, and laboratory supplies - and overpay for most of it. A small number of major distributors control the majority of that flow, inserting their margins into every transaction while leaving buyers unable to compare prices, access smaller suppliers, or see what they are actually paying relative to the market. Siamak Baharloo, a PhD geneticist who spent two decades inside the supply chains he would later redesign, founded Labviva in Boston in 2017 to fix this. In 2025, after doubling revenue in a single year and closing a $25 million Series B round, the company has moved from niche platform to preferred infrastructure for some of the world's largest pharmaceutical organizations - not because the product got better in isolation, but because the industry's cost pressures finally made the problem impossible to ignore.

The Problem No One Was Solving

Pharmaceutical R&D budgets are under pressure from every direction. The Inflation Reduction Act has compressed expected drug revenues at the top line. Federal research funding has faltered. Tariffs on imported chemicals are adding costs at the bottom. According to Labviva's own analysis, tariffs alone are pushing an additional $1.25 billion per year in costs onto R&D labs and chemical consumers across the industry. And yet, inside that squeeze, one of the most expensive inefficiencies in the system - the procurement layer - had barely been touched.

The life sciences supply chain runs on a model built for a different era. Large pharmaceutical companies, biotech firms, and research universities have historically funneled the bulk of their purchases through a small number of major distributors. Fisher Scientific, VWR, Sigma-Aldrich - these companies provide convenience and consolidated invoicing. They also add cost. Every reagent, every consumable, every chemical that passes through a distributor carries a markup that the buying organization cannot easily see, compare, or challenge. The researcher ordering antibodies has no idea whether the same product is available directly from the manufacturer at a lower price. The procurement team running the ERP has no mechanism to surface that comparison automatically. And the distributor, who has a vested interest in maintaining its margin, has no reason to offer it.

Siamak Baharloo saw this from the inside. A PhD geneticist from UCSF who spent more than two decades building digital marketing and ecommerce channels for companies including Thermo Fisher Scientific, Life Technologies, MilliporeSigma, and Sartorius, Baharloo had an unusually complete view of both sides of the transaction. He understood how manufacturers priced their products, how distributors captured margin in the middle, and how researchers and procurement teams at the end of the chain were largely in the dark about both. In 2017, he co-founded Labviva in Boston to dismantle that structure.

The Neutral Marketplace Model

Labviva's core proposition is straightforward: connect life sciences buyers directly to 90% of all manufacturers and suppliers in the market, apply AI to normalize, compare, and recommend across that universe, and do it in a way that integrates invisibly with the procurement systems pharma companies already use. The company calls this a neutral marketplace model - a platform with no stake in steering buyers toward any particular supplier, because Labviva's economics do not depend on distributor relationships.

The platform aggregates more than 15 million products from 18,000 manufacturers and links directly into SAP Ariba, JAGGAER, Oracle Procurement Cloud, Microsoft Dynamics 365, and Coupa. A procurement professional at a major pharmaceutical company does not need to abandon their existing software stack to use it. Labviva sits as a layer on top, providing what the ERP cannot - competitive price comparison, supplier diversity scoring, AI-driven demand forecasting, and catalog harmonization across thousands of products with inconsistent naming conventions and part numbers.

That last element is harder than it sounds. The life sciences catalog problem is its own subspecialty. A single antibody can be listed differently by twenty suppliers, referenced by different catalog numbers, and mapped to different scientific applications depending on who is describing it. Labviva uses natural language processing and large language models to harmonize product attributes across catalogs, enabling its search to work the way a scientist thinks rather than the way a distributor catalogs. A researcher can enter a chemical name, and the platform will automatically generate chemical structures, relevant EHS regulatory information, and purchasing options across multiple suppliers simultaneously.

The financial impact of this is not incremental. Organizations using the Labviva platform report an average 20% reduction in managed spend in the first year. Its inventory management system, which automates stock monitoring and reorder forecasting, drives sourcing and restocking cost reductions of up to 41%. These are not projections - they come from deployments at institutions including Regeneron, Takeda, Bluebird Bio, Johns Hopkins, the University of California system, and a top-ten U.S. research university with a $3 billion annual research budget that saved 13% in the first year of implementation.

A Breakout Year Built on Budget Pressure

The timing of Labviva's growth arc is not coincidental. The pressures bearing down on pharma R&D in 2024 and 2025 - tighter revenue expectations, funding constraints, rising input costs - created the exact conditions in which procurement efficiency moves from a back-office concern to a strategic priority. As R&D budgets tightened, CFOs and procurement leaders at pharmaceutical companies began asking hard questions about where spend was going. Labviva had the answer and the infrastructure to act on it.

Over fiscal year 2024, Labviva doubled its revenue and tripled transactions on its platform. On January 13, 2025, the company announced the close of a $25 million Series B round, bringing total funding to $55 million. The round was led by 53 Stations, whose co-founder and managing partner Jason Pritzker joined Labviva's board of directors. Existing investors Biospring Partners, B Capital Group, and Glasswing Ventures all continued their backing. Pritzker, speaking at the announcement, described Labviva as having transitioned in a single year from the industry's best-kept secret to the go-to resource for accelerating the pace of science.

The capital deployment that followed was deliberate and fast. In May 2025, Labviva established an international headquarters at 344-354 Gray's Inn Road in London's Kings Cross life sciences corridor, appointing Dr. Carlo Iannicola - a 15-year Roche Diagnostics veteran who had led oncology business across Europe, the Middle East, Africa, and Latin America - as general manager of Europe. In June, the company rounded out its global leadership bench with three senior appointments: Renika Sehgal as Chief Operating and Financial Officer, Jennifer Olszewski as Chief Marketing Officer, and Nick Premnath as SVP of Commercial Strategy. The same month, it debuted HarperChem, an AI-powered chemical search and inventory suite that allows laboratories to source, store, and replenish chemical inventories with automated compliance and EHS documentation built in.

The Competitive Moat

The life sciences tools space is not short of vendors claiming AI capability, but Labviva's structural position is harder to replicate than a feature set. The network effect matters here. A marketplace that aggregates 90% of suppliers - including small, local, and green-certified businesses that most legacy procurement platforms would never surface - creates value through breadth that a single distributor or a software vendor without that supplier base cannot match. Smaller manufacturers struggling to access large pharma buyers because of the overhead of distributor contracting gain direct visibility on Labviva. Buyers looking to meet sustainability or supplier diversity targets gain search filters and configurable badges that route spend accordingly. Neither side has to change their underlying operations to participate.

The neutrality of the model is also a harder-to-replicate strategic asset than it may appear. Distributors are structurally unable to build a neutral platform - they have too much invested in their own margins and supplier relationships to offer genuine price transparency. A distributor-built marketplace would always be tilted. Labviva's independence from any particular supplier or distributor relationship is the foundation of the trust that has led firms like Regeneron to build their internal procurement marketplace - the Regeneron Marketplace - on top of the Labviva platform, presenting it at industry conferences as a case study in procurement transformation. Takeda similarly showcased its Labviva implementation at the R&D Procurement and Sourcing in Pharma Summit in Boston in June 2025, with panelists from Takeda's R&D operations and procurement teams walking through how a neutral, data-driven approach to inventory management had reduced waste and improved supply control.

The Bigger Bet

AI in life sciences is forecast to reach $11 billion in annual market value by 2033. Most of that conversation has centered on drug discovery, clinical trial optimization, and molecule design - the science-facing applications that generate headlines. Labviva is making a different bet: that the operational layer, the buy side of research, will prove equally valuable as pharmaceutical companies are forced to extract efficiency from every part of their cost structure.

That bet looks well-positioned. The forces driving adoption are structural, not cyclical. Budget pressure on pharma R&D does not reverse when a single policy changes. Supply chain fragility, demonstrated during COVID and reinforced by tariff and trade disruptions in 2025, has permanently elevated the strategic importance of procurement resilience. The regulatory environment in Europe is tightening, with the EU Critical Medicines Act adding compliance considerations that make supplier transparency more important. And the demographic reality of pharma research - thousands of scientists who think in terms of scientific applications, not catalog part numbers - creates a persistent demand for interfaces that understand how researchers search.

Siamak Baharloo built Labviva by understanding a problem that the industry had accepted as unsolvable: that sophisticated pharmaceutical companies would permanently overpay for reagents and chemicals because the alternative was too hard to manage. Labviva made it manageable. In doing so, it positioned itself at the one chokepoint in the life sciences value chain where dollars are reliably lost, in large amounts, at every institution in the industry. The Series B, the European launch, the HarperChem rollout, the Regeneron and Takeda deployments - these are not the story of an AI company that got lucky with a hot technology cycle. They are the story of a platform that solved a real structural problem, at the right moment in the market's history, with exactly the right neutrality to be trusted.